CO2019007023A2 - Antagonistas de integrinas - Google Patents

Antagonistas de integrinas

Info

Publication number
CO2019007023A2
CO2019007023A2 CONC2019/0007023A CO2019007023A CO2019007023A2 CO 2019007023 A2 CO2019007023 A2 CO 2019007023A2 CO 2019007023 A CO2019007023 A CO 2019007023A CO 2019007023 A2 CO2019007023 A2 CO 2019007023A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical agents
compounds
integrins
integrin antagonists
αvβ8
Prior art date
Application number
CONC2019/0007023A
Other languages
English (en)
Inventor
David W Griggs
Peter G Ruminski
Scott Seiwert
Original Assignee
Univ Saint Louis
Indalo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saint Louis, Indalo Therapeutics Inc filed Critical Univ Saint Louis
Publication of CO2019007023A2 publication Critical patent/CO2019007023A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente exposición proporciona agentes farmacéuticos, incluidos los de la fórmula: (I) en donde las variables se definen en el presente documento. También se proporcionan composiciones farmacéuticas, equipos y artículos de fabricación que comprenden dichos agentes farmacéuticos. También se proporcionan métodos de uso de los agentes farmacéuticos. Los compuestos pueden utilizarse para la inhibición o el antagonismo de las integrinas αVβ1 y/o α5β1. En algunas modalidades, los compuestos proporcionados en el presente documento muestran una actividad inhibitoria o antagonista reducida de las integrinas αVβ3, αVβ5, αVβ6, αVβ8 y/o αIIbβ3.
CONC2019/0007023A 2016-12-29 2019-06-28 Antagonistas de integrinas CO2019007023A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662440253P 2016-12-29 2016-12-29
US201762471882P 2017-03-15 2017-03-15
PCT/US2017/068801 WO2018132268A1 (en) 2016-12-29 2017-12-28 Integrin antagonists

Publications (1)

Publication Number Publication Date
CO2019007023A2 true CO2019007023A2 (es) 2019-07-31

Family

ID=62840040

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0007023A CO2019007023A2 (es) 2016-12-29 2019-06-28 Antagonistas de integrinas

Country Status (14)

Country Link
US (1) US11306084B2 (es)
EP (1) EP3562826A4 (es)
JP (1) JP2020504120A (es)
KR (1) KR20190100232A (es)
CN (1) CN110177787A (es)
AU (1) AU2017393297A1 (es)
BR (1) BR112019012515A2 (es)
CA (1) CA3045491A1 (es)
CO (1) CO2019007023A2 (es)
IL (1) IL267686A (es)
MX (1) MX2019007797A (es)
PH (1) PH12019501514A1 (es)
RU (1) RU2019116820A (es)
WO (1) WO2018132268A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020504120A (ja) 2016-12-29 2020-02-06 セントルイス ユニバーシティ インテグリンアンタゴニスト
RU2769702C2 (ru) 2017-02-28 2022-04-05 Морфик Терапьютик, Инк. Ингибиторы интегрина avb6
EP3760202A1 (en) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
EP4086254A1 (en) 2018-08-29 2022-11-09 Morphic Therapeutic, Inc. Integrin inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119098B2 (en) 2000-06-15 2006-10-10 Pharmacia Corporation Heteroarylakanoic acids as intergrin receptor antagonists
AU2003297408A1 (en) 2002-12-20 2004-07-22 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
US20050043344A1 (en) 2002-12-20 2005-02-24 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists derivatives
EP1572691A1 (en) 2002-12-20 2005-09-14 Pharmacia Corporation Pyrazole compounds as integrin receptor antagonists derivatives
JP6215324B2 (ja) * 2012-07-18 2017-10-18 セントルイス ユニバーシティ インテグリンアンタゴニストとしてのβアミノ酸誘導体
US8716226B2 (en) * 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
EA038164B1 (ru) 2016-11-08 2021-07-16 Бристол-Маерс Сквибб Компани 3-замещенные пропановые кислоты в качестве ингибиторов интегрина v
EA201991123A1 (ru) 2016-11-08 2019-11-29 ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV
MA46746A (fr) 2016-11-08 2019-09-18 Bristol Myers Squibb Co Amides d'azole et amines en tant qu'inhibiteurs d'intégrine alpha v
MA46744A (fr) 2016-11-08 2019-09-18 Bristol Myers Squibb Co Composés mono et spirocycliques contenant du cyclobutane et de l'azétidine en tant qu'inhibiteurs de l'intégrine alpha v
DK3538528T3 (da) 2016-11-08 2021-02-15 Bristol Myers Squibb Co Pyrrolamider som alpha v-integrinhæmmere
JP2020504120A (ja) 2016-12-29 2020-02-06 セントルイス ユニバーシティ インテグリンアンタゴニスト
EP3760202A1 (en) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
BR112020026278A2 (pt) 2018-06-27 2021-04-06 Pliant Therapeutics, Inc. Compostos de aminoácidos com ligantes não ramificados e métodos de uso
US20210284638A1 (en) 2018-07-03 2021-09-16 Saint Louis University ALPHAvBETA1 INTEGRIN ANTAGONISTS

Also Published As

Publication number Publication date
MX2019007797A (es) 2019-10-21
US11306084B2 (en) 2022-04-19
WO2018132268A8 (en) 2019-06-20
WO2018132268A1 (en) 2018-07-19
JP2020504120A (ja) 2020-02-06
PH12019501514A1 (en) 2020-09-14
CN110177787A (zh) 2019-08-27
AU2017393297A1 (en) 2019-06-13
CA3045491A1 (en) 2018-07-19
EP3562826A1 (en) 2019-11-06
RU2019116820A (ru) 2021-01-29
US20190345155A1 (en) 2019-11-14
EP3562826A4 (en) 2020-08-26
BR112019012515A2 (pt) 2019-11-19
KR20190100232A (ko) 2019-08-28
IL267686A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
CO2019007023A2 (es) Antagonistas de integrinas
CO2018008705A2 (es) Compuestos de piperidina sustituido y su uso
CL2015000942A1 (es) Compuestos de benceno sustituido.
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
CL2015001756A1 (es) Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion.
UY34797A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
BR112015032541A2 (pt) conservação de composições para cuidados pessoais
PE20131493A1 (es) Amidas aminoindanes con una alta actividad fungicida y sus composiciones fitosanitarias
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2013003313A1 (es) Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8.
CL2015003569A1 (es) “compuestos derivados de (aril ó heteroaril)metil-2-(aril, heterociclil, cicloalquil ó alquil)-1,3-dioxan-metoxi-fenil-piperazin-1-il-fenil-heterociclil sustituido; composición farmacéutica que los comprende; su uso en el tratamiento de la fibrosis”. pct
UY34480A (es) Compuestos de 2-(fenilo sustituido)-ciclopentan-1,3-diona y derivados de los mismos, composiciones y métodos para controlar malezas.
CL2018000057A1 (es) Composiciones farmacéuticas que comprenden un antagonista de la integrina alfa4 para uso en el tratamiento de afecciones inflamatorias oculares
CO2019009005A2 (es) Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
CO2019007888A2 (es) Inhibidores selectivos de jak1
RS54716B1 (en) HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS
BR112015008389A2 (pt) compostos úteis na síntese de compostos de benzamida
CO2021010930A2 (es) Hidroxipiridoxazepinas como activadores de nrf2
BR112018013548A2 (pt) lenço não tecido, embalagem
BR112017007881A2 (pt) artigo de controle de odor
TR201901516T4 (tr) Nöroprotektif ajanlar ve bunların kullanımları.
AR113270A1 (es) Compuesto de heteroarilo con contenido de nitrógeno y su uso farmacéutico
AR098568A1 (es) Agente químico agrícola u hortícola, método para el control de enfermedades de las plantas, y producto para el control de enfermedades de las plantas
AR078352A1 (es) 5-(3,4-dicloro-fenil) -n- (2-hidroxi - ciclohexil) -6- (2,2,2 -trifluor-etoxi) nicotinamida y sales de la misma